MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1158/1078-0432.ccr-07-0778

Медицинская библиотека · Clinical cancer research : an official journal of the American Association for Cancer Research · 2007

A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone.

Taskinen Minna, Karjalainen-Lindsberg Marja-Liisa, Nyman Heidi, Eerola Leena-Maija, Leppä Sirpa

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

PURPOSE: Tumor-associated macrophage (TAM) content predicts survival in follicular lymphoma (FL) patients treated with chemotherapy. The aim of this study was to determine how combination of rituximab with chemotherapy influences TAM-associated clinical outcome.

EXPERIMENTAL

DESIGN

Expression of a macrophage marker, CD68, was determined immunohistochemically from FL samples of 96 patients treated with rituximab and cyclophosphamide-Adriamycin-vincristine-prednisone regimen. Of them, 71 received therapy at diagnosis and 25 at relapse. Neutrophil and CD3+ lymphocyte counts were also measured. The median follow-up time for the cohort was 54 months. Fourty-five patients previously treated with chemotherapy served as a control group.

RESULTS

Consistent with previous studies, high TAM amount was associated with adverse outcome in chemotherapy-treated patients (P = 0.026). In contrast, after rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone regimen, high TAM content correlated with longer survival rates. According to Kaplan Meier estimates, the median progression free survival (PFS) was not reached for patients with high TAM content compared with 45 months for patients with low TAM scores (P = 0.006). A trend toward a better overall survival (OS) at 5 years was also observed for patients with high TAM content (OS, 97% versus 90%, P = 0.116). The positive prognostic value of TAMs was seen both for the patients treated at diagnosis and at relapse. In multivariate analyses, TAM content remained an independent prognostic factor for OS and PFS. Neutrophil and CD3+ lymphocyte counts did not correlate with outcome.

CONCLUSIONS

The data suggest that high TAM score is associated with a favorable prognosis in FL patients treated with immunochemotherapy.

Для цитирования: Taskinen Minna, Karjalainen-Lindsberg Marja-Liisa, Nyman Heidi, Eerola Leena-Maija, Leppä Sirpa. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone.. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007. DOI: 10.1158/1078-0432.ccr-07-0778.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.